ClinicalTrials.gg
Not yet recruitingNCT07558018NOCAWTUpdated Nov 10, 2026

Evaluation of the Systemic Microcirculation as a Surrogate for Coronary Microcirculation in Women With ANOCA

An observational study in Angina, Microvascular, sponsored by National Institute of Cardiology, Laranjeiras, Brazil. Not yet recruiting. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by National Institute of Cardiology, Laranjeiras, Brazil · Observational

How we know

Updated Nov 10, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The primary objective of this project is to validate a multi-modal systemic microvascular phenotyping platform-combining Laser Speckle Contrast Imaging (LSCI) and Sublingual Handheld Videomicroscopy (IDF imaging)-as a non-invasive surrogate for coronary microvascular function in women with ANOCA (Angina with Non-Obstructive Coronary Arteries). We aim to demonstrate that systemic microvascular signatures (microvascular reactivity and density) can predict coronary endotypes with high accuracy, potentially reducing the need for invasive diagnostics.

Read the detailed description

The study will involve women aged 18 to 65 years, with stable anginal chest pain and no coronary artery disease (ANOCA) (absence of coronary plaque in coronary angiography or computed tomography coronary angiography - CCTA), recruited at the National Institute of Cardiology (INC). The upper age limit was established to limit the influence of vascular senescence on the results.

02

Conditions studied

  • Angina, Microvascular

Browse trials for

Keywords

  • microcirculation
  • Laser Speckle Contrast Imaging
  • Sublingual videomicroscopy
03

In context

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 46 observational studies indexed under Microvascular Angina.

Browse Microvascular Angina studies →

Lead sponsor

National Institute of Cardiology, Laranjeiras, Brazil is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Patients from a terciary cardiology hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Anginal chest pain

Exclusion criteria

Exclusion Criteria:

  • Malignant neoplasms
  • diseases
  • Acute systemic diseases
  • Pregnancy or lactation
  • Iodine allergy
  • CAD on invasive coronary angiography or coronary computed tomography angiography (CCTA)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • ANOCA

    Symptomatic Group (ANOCA): n = 40 patients with stable angina and non-obstructive coronary arteries.

    Procedure: Investigation of Systemic Endothelial Microvascular Function

  • CONTROL

    Control Group: n = 20 age-matched women without chest pain and without CAD.

    Procedure: Investigation of Systemic Endothelial Microvascular Function

Interventions

  • ProcedureInvestigation of Systemic Endothelial Microvascular Function

    Investigation of Systemic Endothelial Microvascular Function

    Also known as: Myocardial Perfusion Imaging, Sublingual videomicroscopy, Invasive coronary flow determination, Cutaneous Laser Speckle Contrast Imaging

06

What researchers measure

Primary outcomes

  1. Evaluation of endothelium-dependent skin microvascular reactivity.

    Evaluation of systemic microvascular reactivity induced by endothelium-dependent agent (acetylcholine). Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging, coupled with skin iontophoresis of vasodilator agents. Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.

    Time frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.

Secondary outcomes

  1. Evaluation of endothelium-independent skin microvascular reactivity.

    Evaluation of systemic microvascular reactivity induced by endothelium-independent agent (sodium nitroprusside). Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging, coupled with skin iontophoresis of vasodilator agents. Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.

    Time frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.

  2. Evaluation of endothelium-dependent skin microvascular reactivity.

    Evaluation of systemic microvascular reactivity induced by postocclusive reactive hyperemia. Microvascular reactivity will be evaluated using a non-invasive and operator -independent methodology, named laser speckle contrast imaging. Cutaneous microvascular flow will be measured in arbitrary perfusion units, divided by mean arterial pressure, to yield cutaneous vascular conductance.

    Time frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.

  3. Evaluation of sublingual microcirculation.

    Sublingual microcirculatory density and perfusion will be assessed using a handheld camera based on incident dark-field (IDF) imaging.

    Time frame: Microvascular reactivity will be evaluated 20-minute rest in the supine position in a temperature-controlled room.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jan 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 30, 2026
StartEst.
Jan 2027was Aug 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Jan 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Aug 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07558018
Lead sponsor
National Institute of Cardiology, Laranjeiras, Brazil
Responsible party
Eduardo Tibirica, MD, PhD (Senior Researcher, National Institute of Cardiology, Laranjeiras, Brazil) — Principal investigator
First posted
Apr 30, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Eduardo Tibirica, MD, PhD
Contact
etibi@uol.com.br
+55-21-99914-6075

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion